Related Experiment Video

Updated: May 27, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Autophagy activation by rapamycin reduces severity of experimental osteoarthritis

Beatriz Caramés1, Akihiko Hasegawa, Noboru Taniguchi

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.

Annals of the Rheumatic Diseases
|November 16, 2011
PubMed
Abstract

Insights

Rapamycin treatment reduced experimental osteoarthritis severity by activating autophagy, a cellular process crucial for maintaining cartilage health. This suggests that enhancing autophagy could be a promising therapeutic strategy for osteoarthritis.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Rheumatology

Background:

  • Osteoarthritis (OA) is characterized by cartilage degradation and impaired cellular homeostasis.
  • Autophagy, a key cellular recycling process, is deficient in aging and osteoarthritic cartilage.
  • The mammalian target of rapamycin (mTOR) pathway regulates autophagy and is implicated in OA pathogenesis.

Purpose of the Study:

  • To investigate the disease-modifying effects of pharmacological mTOR inhibition on experimental osteoarthritis.
  • To determine if activating autophagy via mTOR inhibition can ameliorate OA-related cartilage damage and inflammation.

Main Methods:

  • Experimental OA was induced in C57Bl/6 mice via ligament transection.
  • Mice received daily intraperitoneal injections of rapamycin (mTOR inhibitor) or vehicle control for 10 weeks.
  • Histopathological analysis, immunohistochemistry, and immunofluorescence were used to assess cartilage and synovium, mTOR signaling, autophagy markers (LC3), and inflammatory markers (IL-1β).

Main Results:

  • Rapamycin treatment inhibited mTOR signaling, evidenced by decreased S6 phosphorylation.
  • Autophagy was activated, indicated by increased LC3 expression.
  • Significant reduction in cartilage degradation (p<0.01) and synovitis (p<0.05) was observed in the rapamycin group.
  • Rapamycin maintained cartilage cellularity and decreased expression of ADAMTS-5 and IL-1β.

Conclusions:

  • Pharmacological inhibition of mTOR with rapamycin demonstrates disease-modifying activity in experimental osteoarthritis.
  • Activation of autophagy by rapamycin contributes to the reduction in OA severity.
  • Targeting autophagy represents a potential therapeutic avenue for managing osteoarthritis.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...